Cost-effectiveness of smoking cessation according to the abstinence rate.

COPD, chronic obstructive pulmonary disease; QALY, quality adjusted life-years; ICER, incremental cost-effectiveness ratio: additional cost (positive values) or savings (negative values) per unit of QALY gained. All values except those corresponding to no intervention (cohorts in which all patients smoke at simulation initiation) represent incremental costs, incremental health outcomes, or incremental cost-effectiveness, as compared to no intervention.慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease，COPD）、质量调整生命年（Quality Adjusted Life-Years，QALY）与增量成本效果比（Incremental Cost-Effectiveness Ratio，ICER）：其中增量成本效果比指每获得1单位质量调整生命年所需额外投入的成本（正值）或节省的成本（负值）。除无干预组（即模拟启动时所有患者均为吸烟者的队列）对应的数值外，其余所有数值均为相较于无干预组的增量成本、增量健康结局或增量成本效果比。